|
1）Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. National kidney foundation hypertension and diabetes executive committees working group. Am J Kidney Dis. 2000; 36: 646-61
|
|
|
|
2）Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the ongoing telmisartan alone and in combination with ramipril global endpoint trial study. J Hypertens. 2009; 27: 1360-9
|
|
|
|
|
|
3）Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med. 2003; 139: 244-52
|
|
|
|
|
|
4）Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol. 2005; 16: 2170-9
|
|
|
|
|
|
5）Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010; 304: 61-8
|
|
|
|
|
|
6）Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med. 1993; 329: 1456-62
|
|
|
|
|
|
7）Haller H, Ito S, Izzo JL, Jr., et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011; 364: 907-17
|
|
|
|
|
|
8）Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the reduction of endpoints in niddm with the angiotensin ii antagonist losartan (renaal) trial. J Am Soc Nephrol. 2007; 18: 1540-6
|
|
|
|
|
|
9）Ruggenenti P, Remuzzi G. Proteinuria: Is the ontarget renal substudy actually off target? Nat Rev Nephrol. 2009; 5: 436-7
|
|
|
|
|
|
10）Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359: 2417-28
|
|
|
|
|
|
11）Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (accomplish): A prespecified secondary analysis of a randomised controlled trial. Lancet. 2010; 375: 1173-81
|
|
|
|
|
|
12）Bakris GL, Toto RD, McCullough PA, et al. Effects of different ace inhibitor combinations on albuminuria: Results of the guard study. Kidney Int. 2008; 73: 1303-9
|
|
|
|
|
|
13）Masuyama T, Tsujino T, Origasa H, et al. Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J. 2012; 76: 833-42
|
|
|
|